var data={"title":"Measles, mumps, rubella, and varicella virus vaccine: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Measles, mumps, rubella, and varicella virus vaccine: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/113242?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=measles-mumps-rubella-and-varicella-virus-vaccine-drug-information\" class=\"drug drug_general\">see &quot;Measles, mumps, rubella, and varicella virus vaccine: Drug information&quot;</a> and <a href=\"topic.htm?path=measles-mumps-rubella-and-varicella-virus-vaccine-patient-drug-information\" class=\"drug drug_patient\">see &quot;Measles, mumps, rubella, and varicella virus vaccine: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1433435\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>ProQuad</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10407944\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Priorix-Tetra;</li>\n      <li>ProQuad</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2886917\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Vaccine</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Vaccine, Live Virus</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2886926\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=measles-mumps-rubella-and-varicella-virus-vaccine-drug-information\" class=\"drug drug_general\">see &quot;Measles, mumps, rubella, and varicella virus vaccine: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Consult CDC/ACIP annual immunization schedules for additional information including specific detailed recommendations for catch-up scenarios and/or care of patients with high-risk conditions. According to ACIP, doses administered &le;4 days before minimum interval or age are considered valid; however, local or state mandates may supersede this timeframe (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Primary immunization:</b> Children 12 months to 12 years: ProQuad: SubQ: 0.5 mL per dose. A complete immunization series for measles, mumps, rubella, and varicella requires 2 doses of all components, administered as either the combination product (MMRV-Proquad) or as separate MMR and varicella vaccines. The first dose is usually administered at 12 to 15 months of age. The second dose is administered at 4 to 6 years of age; second dose may be administered before age 4 if needed, as long as &ge;3 months have elapsed since the first dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CDC (ACIP) recommendations: For children receiving their first dose at 12 to 47 months of age, either the MMRV combination vaccine or separate MMR and varicella vaccines can be used; however, the ACIP prefers administration of separate MMR and varicella vaccines as the first dose in this age group unless the parent or caregiver expresses preference for the MMRV combination. For children receiving the first dose at &ge;48 months or their second dose at any age, use of MMRV is preferred. The ACIP recommends that children with a personal or family history of seizures be vaccinated with separate MMR and varicella vaccines, as opposed to the MMRV combination vaccine (CDC/ACIP [Marin 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Allow at least 1 month between administering a dose of a measles-containing vaccine (eg, M-M-R II) and ProQuad.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Allow at least 3 months between administering a varicella-containing vaccine (eg, Varivax) and ProQuad.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1582151\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Injection, powder for reconstitution [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ProQuad: Measles virus &ge;3.00 log<sub>10</sub> TCID<sub>50</sub>, mumps virus &ge;4.3 log<sub>10</sub> TCID<sub>50</sub>, rubella virus &ge;3.00 log<sub>10</sub> TCID<sub>50</sub>, and varicella virus &ge;3.99 log<sub>10</sub> PFU [contains albumin (human), bovine serum, chicken egg protein, gelatin, neomycin, sorbitol, and sucrose (&le;21 mg/vial)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ProQuad: Measles virus &ge;3.00 log<sub>10</sub> TCID<sub>50</sub>, mumps virus &ge;4.3 log<sub>10</sub> TCID<sub>50</sub>, rubella virus &ge;3.00 log<sub>10</sub> TCID<sub>50</sub>, and varicella virus &ge;3.99 log<sub>10</sub> PFU [contains recombinant albumin (human), bovine serum, chicken egg protein, gelatin, neomycin, sorbitol, and sucrose (&le;21 mg/vial)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1433437\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25734127\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">In the US, the appropriate CDC-approved Vaccine Information Statement (VIS) must be provided to the patient prior to administering each dose of this vaccine; VIS is available at <a target=\"_blank\" href=\"http://www.cdc.gov/vaccines/hcp/vis/vis-statements/mmrv.html&amp;token=03S8ugZauTiHyhvv3nRjemTZhqTyJ/g1ZFFhVKOx8KN0aGvh82vX9gUZj3JVzLLisSCL+KlKN9GREAQzoH+pCw==&amp;TOPIC_ID=12990\" target=\"_blank\">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/mmrv.html</a>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2886927\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: <b>Note:</b> Disinfectants (eg, alcohol) may inactivate the attenuated viruses in the vaccine. Allow disinfectant adequate time to evaporate from skin prior to administration. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection (ACIP [Kroger 2017]). To prevent syncope related injuries, adolescents and adults should be vaccinated while seated or lying down (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">SubQ: Administer within 30 minutes of reconstitution. Administer subcutaneously into the anterolateral aspect of the thigh or deltoid region of arm; not for IV administration. US law requires that the date of administration, name of manufacturer, lot number, and administering person&rsquo;s name, title, and address be entered into patient's permanent medical record.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1582141\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder for injection: Before reconstitution, store the lyophilized vaccine between -50&deg;C and -15&deg;C (-58&deg;F and 5&deg;F) in a reliably maintained freezer (eg, chest, frost-free) for up to 18 months. Use of dry ice may subject the vaccine to temperatures colder than -50&deg;C (-58&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">May store refrigerated at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for up to 72 hours prior to reconstitution. Discard any vaccine stored at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) that is not used within 72 hours of removal from -15&deg;C (5&deg;F) storage. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protect the vaccine from light at all times.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Canadian products:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ProQuad:  During shipment, vaccine must be maintained at a temperature between -50&deg;C and +8&deg;C (-58&deg;F and 46&deg;F). Use of dry ice may subject the vaccine to temperatures colder than -50&deg;C. Before reconstitution, store refrigerated at a temperature of 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) or in a freezer at temperatures above -50&deg;C (-58&deg;F); if subsequently transferred to a refrigerator, the vaccine may be placed back in the freezer. May administered provided total (cumulative multiple excursions) time out of refrigeration (prior to reconstitution, at temperatures between 8&deg;C and 25&deg;C) does not exceed 14 hours. These are not, however, recommendations for storage. Protect the vaccine from light at all times.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Priorix-Tetra: Store refrigerated at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Do not freeze. Store in the original packaging in order to protect from light. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Reconstituted vaccine: Discard reconstituted vaccine if it is not used within 30 minutes. Do not freeze reconstituted vaccine. Protect from light at all times.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Canadian products:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">ProQuad: Use as soon as possible after reconstitution. Discard if not used within 30 minutes. Store reconstituted vaccine in the vaccine vial in a dark place at room temperature. Do not freeze reconstituted vaccine. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Priorix-Tetra: Administer as soon as possible. May be refrigerated (2&deg;C to 8&deg;C; 36&deg;F to 46&deg;F) for up to 8 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diluent: Store diluent separately at room temperature (20&deg;C to 25&deg;C [68&deg;F to 77&deg;F]), or in a refrigerator (2&deg;C to 8&deg;C [36&deg;F to 46&deg;F]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2886918\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">To provide active immunity to measles, mumps, rubella, and varicella viruses (FDA approved in ages 12 months to 12 years) </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination against measles, mumps, rubella, and varicella in healthy children; the first dose should be given at 12 to 15 months of age and the second dose at 4 to 6 years of age. For children receiving their first dose at 12 to 47 months of age, either the MMRV combination vaccine or separate MMR and varicella vaccines can be used. The ACIP prefers administration of separate MMR and varicella vaccines as the first dose in this age group particularly for children with a personal or family history of seizures (CDC/ACIP [Marin 2010]) unless the parent or caregiver expresses preference for the MMRV combination. For children receiving the first dose at &ge;48 months or their second dose at any age, use of MMRV is preferred. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23780480\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">MMRV (measles, mumps, rubella, and varicella) vaccine may be confused with MMR (measles, mumps and rubella virus) vaccine</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">MMRV (measles, mumps, rubella, and varicella) vaccine may be confused with MPSV (meningococcal polysaccharide vaccine; MPSV4 is the correct abbreviation)</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1582134\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Also refer to Measles, Mumps, and Rubella Vaccine (M-M-R II) and Varicella Virus Vaccine (Varivax) monographs for additional adverse reactions reported with those agents.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Drowsiness, irritability</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Eczema, morbilliform rash, pruritus, rash at injection site, rubella-like rash, skin rash, varicella-like rash, vesicular eruption, viral exanthem</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Diarrhea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Bleeding at injection site, bruising at injection site, erythema at injection site, pain at injection site (pain, tenderness, soreness), swelling at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Nasopharyngitis, rhinorrhea, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever (&ge;38.9&deg;C [&ge;102&deg;F])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Abdominal pain, abnormal dreams, acute disseminated encephalomyelitis, agitation, anaphylactoid reaction, anaphylaxis, angioneurotic edema, apathy, aplastic anemia, arthralgia, arthritis, aseptic meningitis, ataxia, atypical measles, Bell's palsy, brain disease, bronchitis, bronchospasm, candidiasis, cellulitis, cerebrovascular accident, convulsions (including afebrile events), dizziness, encephalitis, epididymitis, epistaxis, erythema multiforme, extravasation, eyelid edema (in immunocompromised individuals), facial edema, febrile seizures, flatulence, Guillain-Barr&eacute; syndrome, headache, hematochezia, herpes simplex infection, herpes zoster, hypersomnia, IgA vasculitis (Henoch-Sch&ouml;nlein purpura [immunoglobulin A vasculitis]/acute hemorrhagic edema of infancy), impetigo, infection, inflammation, influenza, injection site reaction (burning and/or stinging of short duration, discoloration, eczema, edema/swelling, hematoma, hive-like rash, induration, lump, vesicles, wheal and flare), lip disease, lymphadenitis, lymphadenopathy (regional), measles, musculoskeletal pain, myalgia, necrotizing retinitis, nerve deafness, nervousness, oculomotor nerve paralysis, optic neuritis, optic papillitis, oral mucosa ulcer, orchitis, otalgia, pain (hip, leg, neck), panniculitis, paresthesia, parotitis, parotitis (disseminated), peripheral edema, pneumonia, polyneuropathy, pulmonary congestion, pulmonary infection, purpura, retinitis, retrobulbar neuritis, rhinitis, rough skin, sinusitis, skin infection, skin sclerosis, sneezing, sore throat, Stevens-Johnson syndrome, subacute sclerosing panencephalitis, sunburn, swelling, syncope, thrombocytopenia, transverse myelitis, trauma, tremor, varicella (vaccine strain), venipuncture site hemorrhage, viral infection (rubella vaccine), warm sensation at injection site, wheezing, xeroderma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1582125\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling:</i> Hypersensitivity to this vaccine, measles-, mumps-, rubella-, and/or varicella-containing vaccines, or any component of the formulation, including gelatin; history of anaphylactic reactions to neomycin; individuals with blood dyscrasias, leukemia, lymphomas, or other malignant neoplasms affecting the bone marrow or lymphatic systems; those receiving immunosuppressive therapy (including high-dose systemic corticosteroids); primary and acquired immunodeficiency states (including AIDs or symptomatic HIV; cellular immune deficiencies; hypogammaglobulinemic and dysgammaglobulinemic states); family history of congenital or hereditary immunodeficiency (until immune competence in the vaccine recipient is demonstrated); active untreated tuberculosis; current febrile illness with fever &gt;38.5&deg;C (&gt;101.3&deg;F); pregnancy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Priorix-Tetra: Hypersensitivity to this vaccine, measles-, mumps-, rubella-, and/or varicella-containing vaccines, or any component of the formulation, including neomycin; pregnancy; severe humoral or cellular (primary or acquired) immunodeficiency.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1582126\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Febrile seizures: Children 12 to 23 months of age have been reported to have a higher risk of developing febrile seizures with the use of the combination product (MMRV) compared to administration of MMR and varicella separately. Because it is uncommon for a child to have their first febrile seizure after 4 years of age, the ACIP recommends the use of the combination MMRV vaccine for children receiving their first dose at &ge;48 months or their second dose at any age. The ACIP recommends that children with a personal or family history of seizures be vaccinated with separate MMR and varicella vaccines, as opposed to the MMRV combination vaccine. For children receiving their first dose at 12 to 47 months of age, either the MMRV combination vaccine or separate MMR and varicella vaccines can be used. The ACIP prefers administration of separate MMR and varicella vaccines as the first dose in this age group unless the parent or caregiver expresses preference for the MMRV combination. Parents and caregivers should be provided with the benefits and risks of both options (CDC/ACIP [Marin 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Defer administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Kroger 2017]). Use is contraindicated with fever &gt;38.5&deg;C (&gt;101.3&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; CNS disorders: Use with caution in patients with history of cerebral injury, seizures, or other conditions where stress due to fever should be avoided. Children with a personal or family history of seizures should be vaccinated with separate MMR and varicella vaccines, as opposed to the MMRV combination vaccine (CDC/ACIP [Marin 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; HIV: Safety and efficacy of this combination vaccine have not been established in patients with HIV infection. Use is contraindicated in patients with AIDS or symptomatic HIV.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombocytopenia: Use with caution in patients with thrombocytopenia and those who develop thrombocytopenia after first dose; thrombocytopenia may worsen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tuberculosis: Defer vaccination in patients with active untreated tuberculosis. Use is contraindicated in patients with active untreated tuberculosis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immune globulins: Recent administration of immune globulins may interfere with immune response. Guidelines with suggested administration intervals are available (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Salicylates: Avoid use of salicylates for 6 weeks following vaccination; varicella may increase the risk of Reye's syndrome.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist. The use of combination vaccines is generally preferred over separate injections, taking into consideration provider assessment, patient preference, and potential adverse events. When using combination vaccines, the minimum age for administration is the oldest minimum age for any individual component; the minimum interval between dosing is the greatest minimum interval between any individual components. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered immunocompetence: Use is contraindicated in patients with immunosuppression, including those receiving immunosuppressive therapy (including high-dose systemic corticosteroids). In general, live vaccines should be administered &ge;4 weeks prior to planned immunosuppression and avoided within 2 weeks of immunosuppression when feasible; live vaccines should not be administered for at least 3 months after immunosuppressive therapy (ACIP [Kroger 2017]; IDSA [Rubin 2014]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Albumin: Some products may contain albumin; products containing human albumin may carry a remote risk of viral transmission, including a theoretical risk of Creutzfeldt-Jakob disease transmission.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Egg allergy: Vaccine contains trace amounts of chick embryo antigen. Use caution in patients with history of immediate hypersensitivity/anaphylactic reactions following egg ingestion. Generally, the vaccine can be safely administered to persons with an egg allergy (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gelatin: Some products may contain gelatin. Use is contraindicated in patients with a history of anaphylactic/anaphylactoid reaction to gelatin.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neomycin: Manufactured with neomycin. Use is contraindicated in patients with history of anaphylactic/anaphylactoid reactions to neomycin. Contact dermatitis due to neomycin is not a contraindication to the vaccine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antipyretics: Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2017]). One study reported that routine prophylactic administration of acetaminophen prior to vaccination to prevent fever decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: The safety and efficacy of this combination vaccine has not been established for postexposure prophylaxis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Use of this vaccine for specific medical and/or other indications (eg, immunocompromising conditions, hepatic or kidney disease, diabetes) is also addressed in the ACIP pediatric Recommended Immunization Schedule (CDC/ACIP [Robinson 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood products: Recent administration of blood or blood products may interfere with immune response. Guidelines with suggested administration intervals are available (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Transmission of virus: Vaccinated individuals should not have close association with susceptible high-risk individuals for 6 weeks following vaccination. High-risk individuals susceptible to the varicella virus include immunocompromised persons, pregnant women without evidence of immunity to varicella, newborns of mothers without evidence of varicella immunity, and infants born &lt;28 weeks' gestation (regardless of maternal immunity); transmission of varicella virus may occur.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26017122\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Safety  and efficacy of this combination vaccine have not been established in patients with HIV infection. Use is contraindicated in patients with AIDS or symptomatic HIV. MMR and varicella individual vaccines have been recommended in children with HIV infection who are asymptomatic and not immunosuppressed (CDC immunologic category 1). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">MMR  and MMRV vaccines are both associated with febrile seizures which may occur during the first 2 weeks following vaccination. Based on preliminary information, fever &ge;102&deg;F occurs more often with MMRV (21.5%) compared to separate MMR and varicella vaccines (14.9%) in children 12 to 23 months of age. Measles-like rash also occurs more often with MMRV (3%) than with separate MMR and varicella vaccines (2.1%) in this age group. Most cases resolve spontaneously. The risk of febrile seizures may be increased twofold in children receiving MMRV at age 12 to 23 months in comparison to separate MMR and varicella vaccines (risk is highest 5 to 12 days after first dose). This is not observed in older children (&ge;47 months of age). Immunization with either MMRV or separate MMR and varicella vaccines offers equivalent immunity with the first dose. Using the combination vaccine provides the child with one less injection. Parents and/or caregivers should be provided with information related to the benefits and risks of both options. The ACIP prefers administration of separate MMR and varicella vaccines as the first dose in this age group unless the parent or caregiver expresses preference for the MMRV combination. Children with a personal or family history of seizures should be vaccinated with separate MMR and varicella vaccines, as opposed to the MMRV combination vaccine (CDC/ACIP [Marin 2010]). Results from a larger study confirm that children who were 12 to 23 months of age when receiving their first dose of MMRV vaccine were at an increased risk of fevers and seizures within 7 to 10 days after vaccination. Healthcare visits for fever and seizures were associated with both MMRV and separate MMR and varicella vaccines; however, the relative risk for seizures following vaccination was most significant with the MMRV vaccine. Seizures occurred most often 8 to 10 days following MMRV vaccination (RR 7.6, p &lt;0.0001), 7 to 10 days following separate MMR and varicella vaccination (RR 4.0, p&lt;0.0001), and 7 to 11 days following MMR vaccination (RR 3.7, p&lt;0.0001); no peak in seizures was observed following varicella vaccine alone. Healthcare visits due to fever also clustered between 7 to 10 days after vaccination with any measles-containing vaccine (MMRV RR 6.1, MMR and varicella RR 4.4, MMR RR 4.3). Following a chart review for verification of seizure type, the rate of febrile seizures was 87% following both MMRV and separate MMR and varicella vaccine administration (Klein 2010). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299649\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1582137\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12990&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">5-Aminosalicylic Acid Derivatives: May enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. The primary concern is the potential development of Reye's Syndrome, a condition that has been associated with the use of salicylates in children with varicella infections.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Axicabtagene Ciloleucel: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of infection may be increased. Axicabtagene Ciloleucel may diminish the therapeutic effect of Vaccines (Live). Management: Avoid live virus vaccines for at least 6 weeks prior to initiation of lymphodepleting therapy, during axicabtagene ciloleucel infusion, and after treatment until full immune recovery is achieved.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AzaTHIOprine: May enhance the adverse/toxic effect of Vaccines (Live). AzaTHIOprine may diminish the therapeutic effect of Vaccines (Live). Management: Low-dose azathioprine (3 mg/kg/day or less) is not considered sufficiently immunosuppressive to create vaccine safety concerns and is not a contraindication for administration of zoster vaccine. Higher doses of azathioprine should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: May enhance the adverse/toxic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Vaccines (Live). Corticosteroids (Systemic) may diminish the therapeutic effect of Vaccines (Live). Management: Doses equivalent to less than 2 mg/kg or 20 mg per day of prednisone administered for less than 2 weeks are not considered sufficiently immunosuppressive to create vaccine safety concerns. Higher doses and longer durations should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Daclizumab: May enhance the adverse/toxic effect of Vaccines (Live). Daclizumab may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dimethyl Fumarate: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, Dimethyl Fumarate may increase the risk of vaccinal infection. Dimethyl Fumarate may diminish the therapeutic effect of Vaccines (Live). Management: Canadian labeling for dimethyl fumarate states that live attenuated vaccine administration is not recommended during treatment.  U.S. labeling does not mention this.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dupilumab: May enhance the adverse/toxic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May enhance the adverse/toxic effect of Vaccines (Live). Vaccinal infections may develop. Fingolimod may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immune Globulins: May diminish the therapeutic effect of Vaccines (Live). Management: Consult full interaction monograph for dose interval recommendations.  This interaction does not apply to oral Ty21a typhoid vaccine or others listed as exceptions.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<b> Exceptions: </b>AzaTHIOprine; Beclomethasone (Oral Inhalation); Betamethasone (Systemic); Budesonide (Systemic); Corticotropin; Cortisone; Cytarabine (Liposomal); Deflazacort; Dexamethasone (Systemic); Fludrocortisone; Fluticasone (Oral Inhalation); Hydrocortisone (Systemic); Leflunomide; Mercaptopurine; Methotrexate; MethylPREDNISolone; PrednisoLONE (Systemic); PredniSONE; Triamcinolone (Systemic).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: May enhance the adverse/toxic effect of Vaccines (Live). Leflunomide may diminish the therapeutic effect of Vaccines (Live). Management: The ACIP guidelines state that live-attenuated vaccines should generally be avoided for at least 3 months after cessation of immunosuppressant therapy. However, the ACR does not recommend avoiding live vaccines in patients being treated with leflunomide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mercaptopurine: May enhance the adverse/toxic effect of Vaccines (Live). Mercaptopurine may diminish the therapeutic effect of Vaccines (Live). Management: Low-dose 6-mercaptopurine (1.5 mg/kg/day or less) is not considered sufficiently immunosuppressive to create vaccine safety concerns and is not a contraindication for administration of zoster vaccine. Higher doses of mercaptopurine should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: May enhance the adverse/toxic effect of Vaccines (Live). Methotrexate may diminish the therapeutic effect of Vaccines (Live). Management: Low-dose methotrexate (0.4 mg/kg/week or less) is not considered sufficiently immunosuppressive to create vaccine safety concerns. Higher doses of methotrexate should be avoided.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the adverse/toxic effect of Vaccines (Live). Ocrelizumab may diminish the therapeutic effect of Vaccines (Live).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rabies Immune Globulin (Human): May diminish the therapeutic effect of Vaccines (Live). Management: Avoid administering the measles vaccine within 4 months after administration of rabies immune globulin. Avoid administering other live vaccines within 3 months after administration of rabies immune globulin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rho(D) Immune Globulin: May diminish the therapeutic effect of Measles, Mumps, Rubella, and Varicella Virus Vaccine. Management: Do not delay administration of the measles, mumps, rubella, and varicella virus vaccine in women who have recently received Rho (D) immune globulin.  If possible, women should be tested 3 or more months after vaccine administration to ensure immunity.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. Reye's Syndrome may develop.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tisagenlecleucel: May enhance the adverse/toxic effect of Vaccines (Live). Specifically, the risk of infection may be increased. Tisagenlecleucel may diminish the therapeutic effect of Vaccines (Live). Management: Avoid live virus vaccines for two weeks prior to initiation of lymphodepleting therapy, during tisagenlecleucel infusion, and after treatment until full immune recovery is achieved.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tuberculin Tests: Vaccines (Live) may diminish the diagnostic effect of Tuberculin Tests.  Management: If a parenteral live vaccine has been recently administered, a scheduled PPD skin test should not be administered for at least 4-6 weeks following the administration of the vaccine.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): May diminish the therapeutic effect of other Vaccines (Live). Management: Two or more injectable or nasally administered live vaccines not administered on the same day should be separated by at least 28 days (ie, 4 weeks). If not, the vaccine administered second should be repeated at least 4 week later.<b> Exceptions: </b>Adenovirus (Types 4, 7) Vaccine; Cholera Vaccine; Rotavirus Vaccine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May enhance the adverse/toxic effect of Vaccines (Live). Venetoclax may diminish the therapeutic effect of Vaccines (Live). Management: Avoid use of live, attenuated vaccines before, during, or after (prior to B-cell recovery) venetoclax treatment.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1582122\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Use is contraindicated in pregnant females and pregnancy should be avoided for 3 months (per manufacturer labeling) following vaccination. The ACIP and manufacturer of Priorix-Tetra (Canadian product) recommends that pregnancy should be avoided for 1 month following vaccination with any of the individual components of this vaccine.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Any exposures to the vaccine during pregnancy or within 3 months prior to pregnancy should be reported to the manufacturer (Merck &amp; Co, 877-888-4231) or to VAERS (800-822-7967) as suspected adverse reactions.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Refer to the Varicella Virus Vaccine monograph and the Measles, Mumps, and Rubella Virus Vaccine monograph for additional information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7775583\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Rash, fever; observe for syncope for 15 minutes following administration (ACIP [Kroger 2017]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to re-establish adequate cerebral perfusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1582143\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">A live, attenuated virus vaccine that induces active immunity to disease caused by the measles, mumps, rubella, and varicella-zoster viruses.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F22903838\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: At 6 weeks postvaccination of a single dose, the antibody response rate in healthy children 12 to 23 months of age was ~91% to 99%. Following a second dose to children &lt;3 years of age, the observed antibody response rate was ~98% to 99%.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration of action: Antibody levels persist 10 years or longer in most healthy recipients. Refer to the Varicella Virus Vaccine monograph and the Measles, Mumps, and Rubella Virus Vaccine monograph for details.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23670315\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Priorix Tetra (AE, CY, QA, SA, TH);</li>\n      <li>Priorix-Tetra (MT);</li>\n      <li>ProQuad (AT, AU, CZ, ES, HR, IE, IT, LT, NL, NZ, PL, PT, RO, SG, SK);</li>\n      <li>Proquad (DK, HK, HU);</li>\n      <li>PrroQuad (EE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Kim DK, Riley LE, Harriman KH, Hunter P, Bridges CB. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older - United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(5):136-138.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/measles-mumps-rubella-and-varicella-virus-vaccine-pediatric-drug-information/abstract-text/28182599/pubmed\" target=\"_blank\" id=\"28182599\">28182599</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Klein NP, Fireman B, Yih WK, et al, &quot;Measles-Mumps-Rubella-Varicella Combination Vaccine and the Risk of Febrile Seizures,&quot; <i>Pediatrics</i>, 2010, 126(1):e1-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/measles-mumps-rubella-and-varicella-virus-vaccine-pediatric-drug-information/abstract-text/20587679/pubmed\" target=\"_blank\" id=\"20587679\">20587679</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kroger AT, Duchin J, Vazquez M. General best practice guidelines for immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). Available at <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf\" target=\"_blank\">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed April 4, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marin M, Broder KR, Temte JL, Snider DE, Seward JF; Centers for Disease Control and Prevention (CDC). Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). <i>MMWR Recomm Rep</i>. 2010;59(RR-3):1-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/measles-mumps-rubella-and-varicella-virus-vaccine-pediatric-drug-information/abstract-text/20448530/pubmed\" target=\"_blank\" id=\"20448530\">20448530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nolan T, Bernstein DI, Block SL, et al, &quot;Safety and Immunogenicity of Concurrent Administration of Live Attenuated Influenza Vaccine With Measles-Mumps-Rubella and Varicella Vaccines to Infants 12 to 15 Months of Age,&quot; <i>Pediatrics</i>, 2008, 121(3):508-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/measles-mumps-rubella-and-varicella-virus-vaccine-pediatric-drug-information/abstract-text/18310199/pubmed\" target=\"_blank\" id=\"18310199\">18310199</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    ProQuad (measles, mumps, rubella, and varicella virus vaccine live) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prymula R, Siegrist CA, Chlibek R, et al, &quot;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&quot; <i>Lancet</i>, 2009, 374(9698):1339-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/measles-mumps-rubella-and-varicella-virus-vaccine-pediatric-drug-information/abstract-text/19837254/pubmed\" target=\"_blank\" id=\"19837254\">19837254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robinson CL, Romero JR, Kempe A, et al. Advisory Committee on Immunization Practices Recommended Immunization Schedule for Children and Adolescents Aged 18 Years or Younger - United States, 2017. <i>MMWR Morb Mortal Wkly Rep</i>. 2017;66(5):134-135.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/measles-mumps-rubella-and-varicella-virus-vaccine-pediatric-drug-information/abstract-text/28182607/pubmed\" target=\"_blank\" id=\"28182607\">28182607</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/measles-mumps-rubella-and-varicella-virus-vaccine-pediatric-drug-information/abstract-text/24311479/pubmed\" target=\"_blank\" id=\"24311479\">24311479</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12990 Version 116.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F1433435\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F10407944\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F2886917\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F2886926\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F1582151\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F1433437\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F25734127\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F2886927\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F1582141\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F2886918\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F23780480\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F1582134\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F1582125\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F1582126\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26017122\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299649\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F1582137\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F1582122\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F7775583\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F1582143\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F22903838\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F23670315\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12990|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=measles-mumps-rubella-and-varicella-virus-vaccine-drug-information\" class=\"drug drug_general\">Measles, mumps, rubella, and varicella virus vaccine: Drug information</a></li><li><a href=\"topic.htm?path=measles-mumps-rubella-and-varicella-virus-vaccine-patient-drug-information\" class=\"drug drug_patient\">Measles, mumps, rubella, and varicella virus vaccine: Patient drug information</a></li></ul></div></div>","javascript":null}